<DOC>
	<DOCNO>NCT00632125</DOCNO>
	<brief_summary>Cumulative follow-up HX575 epoetin alfa prospectively monitor incidence relevant drug-related adverse event EPO-related lack efficacy among CKD subject receive HX575 epoetin alfa i.v .</brief_summary>
	<brief_title>Post-authorization Safety Study CKD Subjects Receiving HX575 i.v .</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>CKD subject without dialysis treatment Age 18 year Subjects require i.v . ESA treatment Subjects likely remain i.v . ESA treatment 6 month Provision inform consent Systemic immunosuppressive medication drug know adversely affect hemoglobin level Known primary lack efficacy ( LOE ) , unexplained loss effect recombinant erythropoietin product History PRCA aplastic anemia History antierythropoietin antibody Uncontrolled hypertension Pregnant woman nurse mother Women childbearing potential agree maintain effective birth control study treatment period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>CKD subject without dialysis treatment</keyword>
</DOC>